Mối liên hệ giữa protein gắn retinol 4 và transthyretin với mức triglyceride và kháng insulin ở người Thái nông thôn có nguy cơ cao mắc tiểu đường type 2

BMC Endocrine Disorders - Tập 18 - Trang 1-7 - 2018
Karunee Kwanbunjan1, Pornpimol Panprathip1, Chanchira Phosat2, Noppanath Chumpathat3, Naruemon Wechjakwen4, Somchai Puduang1, Ratchada Auyyuenyong5, Ina Henkel6, Florian J. Schweigert6
1Department of Tropical Nutrition and Food Science, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
2Department of Nutrition, Faculty of Public Health, Mahidol University, Bangkok, Thailand
3Faculty of Nursing, Huachiew Chalermprakiet University, Samut Prakan, Thailand
4Faculty of Public Health, Nakhonratchasima Rajabhat University, Nakhon Ratchasima, Thailand
5Department of Food Business and Nutrition, Faculty of Agriculture, Ubon Ratchathani Rajabhat University, Ubon Ratchathani, Thailand
6Institute of Nutritional Science, University of Potsdam, Potsdam, Germany

Tóm tắt

Protein gắn retinol 4 (RBP4), một protein được tiết ra từ các tế bào mỡ và gắn kết trong huyết tương với transthyretin (TTR), đã được liên kết với béo phì, giai đoạn đầu của kháng insulin, hội chứng chuyển hóa và tiểu đường type 2. Mục tiêu của nghiên cứu này là làm sáng tỏ mối quan hệ giữa RBP4, TTR, triglyceride (TG) và nguy cơ tiểu đường type 2 ở các vùng nông thôn của Thái Lan. Chúng tôi đã đo lường nồng độ RBP4, TTR, glucose, triglyceride và insulin trong huyết thanh, cũng như độ nhạy insulin ở 167 tình nguyện viên từ huyện Sung Noen, tỉnh Nakhon Ratchasima, Thái Lan. Phân tích t-test của Student, tương quan Pearson và hồi quy logistic được sử dụng để đánh giá mối quan hệ giữa RBP4, TTR và các chỉ số tiểu đường type 2. Nồng độ RBP4 và TTR, cũng như giá trị đánh giá mô hình homeostatic của kháng insulin (HOMA-IR), đã tăng đáng kể ở những đối tượng có nồng độ triglyceride cao (p < 0,01, p < 0,05, p < 0,05, tương ứng). Mức triglyceride có tương quan với nồng độ RBP4 (r = 0,34, p < 0,001) và nồng độ TTR (r = 0,26, p < 0,01), cũng như giá trị HOMA-IR (r = 0,16, p < 0,05). Sau khi điều chỉnh theo độ tuổi và giới tính, nguy cơ tăng triglyceride cao gấp 3,7 lần (95% CI = 1,42–9,73, p = 0,008) ở tertile RBP4 cao nhất so với tertile thấp nhất. Tương tự, tertile TTR cao nhất và HOMA-IR cũng có nguy cơ tăng triglyceride cao hơn gấp 3,5 (95% CI = 1,30–9,20, p = 0,01) và 3,6 (95% CI = 1,33–9,58, p = 0,01) lần so với các tertile thấp nhất tương ứng. Mối tương quan giữa TTR và glucose trong máu có ý nghĩa thống kê (r = 0,18, p < 0,05), nhưng không tìm thấy mối quan hệ này ở RBP4. Các mối liên hệ của RBP4 và TTR với tình trạng tăng triglyceride và kháng insulin có thể có những tác động quan trọng đối với nguy cơ bệnh tim và đột quỵ.

Từ khóa

#RBP4 #TTR #triglyceride #kháng insulin #tiểu đường type 2 #nông thôn Thái Lan

Tài liệu tham khảo

Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. New Engl J Med. 2006;354:2552–63. Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care. 2006;29:2457–61. Chavez AO, Coletta DK, Kamath S, Cromack DT, Monroy A, Folli F, et al. Retinol-binding protein 4 is associated with impaired glucose tolerance but not with whole body or hepatic insulin resistance in Mexican Americans. Am J Physiol Endocrinol Metab. 2009;296:E758–64. Xu M, Li XY, Wang JG, Wang XJ, Huang Y, Cheng Q, et al. Retinol-binding protein 4 is associated with impaired glucose regulation and microalbuminuria in a Chinese population. Diabetologia. 2009;52:1511–9. Murata M, Saito T, Otani T, Sasaki M, Ikoma A, Toyoshima H, et al. An increase in serum retinol-binding protein 4 in the type 2 diabetic subjects with nephropathy. Endocr J. 2009;56:287–94. Li F, Xia K, Sheikh MS, Cheng J, Li C, Yang T. Retinol binding protein 4 promotes hyperinsulinism induced proliferation of rat aortic smooth muscle cells. Mol Med Rep. 2014;9:1634–40. von Eynatten M, Lepper PM, Liu D, Lang K, Baumann M, Nawroth PP, et al. Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease. Diabetologia. 2007;50:1930–7. Kowalska I, Straczkowski M, Adamska A, Nikolajuk A, Karczewska-Kupczewska M, Otziomek E, et al. Serum retinol binding protein 4 is related to insulin resistance and nonoxidative glucose metabolism in lean and obese women with normal glucose tolerance. J Clin Endocrinol Metab. 2008;93:2786–9. Lewis JG, Shand BI, Frampton CM, Elder PA, Scott RS. Plasma retinol-binding protein is not a marker of insulin resistance in overweight subjects: a three year longitudinal study. Clin Biochem. 2008;41:1034–8. Gavi S, Qurashi S, Stuart LM, Lau R, Melendez MM, Mynarcik DC, et al. Influence of age on the association of retinol-binding protein 4 with metabolic syndrome. Obesity (Silver Spring). 2008;16:893–5. Zanotti G, Berni R. Plasma retinol-binding protein: structure and interactions with retinol, retinoids, and transthyretin. Vitam Horm. 2004;69:271–95. Pandey GK, Balasubramanyam J, Balakumar M, Deepa M, Anjana RM, Abhijit S, et al. Altered circulating levels of retinol binding protein 4 and transthyretin in relation to insulin resistance, obesity, and glucose intolerance in Asian Indians. Endocr Pract. 2015;21:861–9. Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G, et al. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation. 2004;110:2678–86. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 western prospective studies. Circulation. 2007;115:450–8. Murad MH, Hazem A, Coto-Yglesias F, Dzyubak S, Gupta S, Bancos I, et al. The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis. BMC Endocr Disord. 2012;12:2. Henry N. Ginsberg. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106:453–8. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol. 1998;81:18B–25B. International Diabetes Federation. Diabetes atlas, 7th edition. 2017. www.idf.org/diabetesatlas. Accessed 21 June 2017. International Diabetes Federation. WP Region. 2017. https://www.idf.org/our-network/regions-members/western-pacific/members/115-thailand.html. Accessed 21 June 2017. World Health Organization. Cardiovascular disease. 2017. http://www.who.int/cardiovascular_diseases/en/. Accessed 21 June 2017. World Health Organization. Noncommunicable Diseases (NCD) Country Profiles. 2014. http://www.who.int/nmh/countries/tha_en.pdf. Accessed 21 June 2017. National Institutes of Health. Metabolic Syndrome. 2017. https://www.nhlbi.nih.gov/health/health-topics/topics/ms. Accessed 21 June 2017. Raila J, Henze A, Spranger J, Mohlig M, Pfeiffer AFH, Schweigert FJ. Microalbuminuria is a major determinant of elevated plasma retinol-binding protein 4 in type 2 diabetic patients. Kidney Int. 2007;72:505–11. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106:3143–421. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol. 1999;83(9B):25F–9F. Steiner G. Hyperinsulinaemia and hypertriglyceridaemia. J Intern Med Suppl. 1994;736:23–6. Despres JP. The insulin resistance-dyslipidemic syndrome of visceral obesity: effect on patients’ risk. Obes Res. 1998;6:8S–17S. Bjorntorp P. New concepts in the relationship obesity--non-insulin dependent diabetes mellitus. Eur J Med. 1992;1:37–42. Saki F, Ashkani-Esfahani S, Karamizadeh Z. Investigation of the relationship between retinol binding protein 4, metabolic syndrome and insulin resistance in Iranian obese 5-17 year old children. Iran J Pediatr. 2013;23:396–402. Yoshida A, Matsutani Y, Fukuchi Y, Saito K, Naito M. Analysis of the factors contributing to serum retinol binding protein and transthyretin levels in Japanese adults. J Atheroscler Thromb. 2006;13:209–15. Qi Q, Yu Z, Ye X, Zhao F, Huang P, Hu FB, et al. Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. J Clin Endocrinol Metab. 2007;92:4827–34. Mostafaie N, Sebesta C, Zehetmayer S, Jungwirth S, Huber KR, Hinterberger M, et al. Circulating retinol-binding protein 4 and metabolic syndrome in the elderly. Wien Med Wochenschr. 2011;161:505–10. Comucci EB, Vasques AC, Geloneze B, Calixto AR, Pareja JC, Tambascia MA. Serum levels of retinol binding protein 4 in women with different levels of adiposity and glucose tolerance. Arq Bras Endocrinol Metabol. 2014;58:709–14. Ingenbleek Y, Young V. Transthyretin (prealbumin) in health and disease: nutritional implications. Annu Rev Nutr. 1994;14:495–533. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab. 2007;92:2712–9. Cabré A, Lázaro I, Girona J, Manzanares JM, Marimón F, Plana N, et al. The APOA5-1131 T>C variant enhances the association between RBP4 and hypertriglyceridemia in diabetes. Nutr Metab Cardiovasc Dis. 2010;20:243–8. West KM, Ahuja MM, Bennett PH, Czyzyk A, De Acosta OM, Fuller JH, et al. The role of circulating glucose and triglyceride concentrations and their interactions with other “risk factors” as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabetes Care. 1983;6:361–9. Fontbonne A, Eschwège E, Cambien F, Richard JL, Ducimetière P, Thibult N, et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris prospective study. Diabetologia. 1989;32:300–4.
Thông tin
Thông tin xuất bản

BMC Endocrine Disorders

Tập 18

1-7

Thông tin tác giả